13F-HR filed by Wildcat Capital Management, LLC
Wildcat Capital Management, LLC filed this 13F-HR for the quarter ended 2025-03-31, filed 2025-05-02, with 8 holding rows worth $187,387,580.
- Accession
- 0001999371-25-005352
- Filer
- CIK 1582384
- Filed
- 2025-05-02
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2025
A holdings report, 8 entries on the cover page, a total value of $187,387,580 stated on the cover page (in dollars after the unit check, H1), rows summing to $187,387,580 with VALUE read as dollars as filed, 13F file number 028-16579. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| FRONTIER GROUP HLDGS INC COM | 35909R108 | Stock | 28,061,351 | $121,786,263 | dollars as filed | |
| RLX TECHNOLOGY INC | 74969N103 | SPONSORED ADS | 18,046,195 | $33,926,847 | dollars as filed | |
| ACUREN CORP | 00510N102 | COM | 1,500,000 | $16,680,000 | dollars as filed | |
| UROGEN PHARMA LTD | M96088105 | COMMON STOCK | 495,606 | $5,481,402 | dollars as filed | |
| ALLOGENE THERAPEUTICS INC | 019770106 | COM | 2,920,787 | $4,264,349 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 281,859 | $4,053,132 | dollars as filed | |
| KRONOS BIO INC | 50107A104 | COM | 1,297,959 | $1,070,816 | dollars as filed | |
| SILEXION THERAPEUTICS CORP | G1281K122 | SHS NEW | 113,428 | $124,771 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001999371-25-005352 | this filing | 2025-05-02 | acceptance time not in the bulk data set |